Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

NCT06118658 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gastric
Colorectal Adenocarcinoma

Interventions

DRUG: tislelizumab

Sponsor

China Medical University, China